低危mds患者每日或每周三次皮下给予极低剂量地西他滨的.docVIP

ASH DACOGEN PAGE PAGE 1 JJ Proprietary Confidential Time Section Board # Abs No. / Title / Authors Friday，Dec 4th, 2009 Satellite Meeting NA Dr. Jean Pierre Eisai Symposia – “Emerging Strategies for the Treatment of AML/MDS – progress and challenges” Sunday, December 6, 2009: 5:30 PM Conference Auditorium AB (Ernest N. Morial Convention Center) Oral Session NA 119 A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS) 低危MDS患者每日或每周三次皮下给予极低剂量地西他滨的II期随机研究 Guillermo Garcia-Manero, MD1, Daniel R. Couriel, MD2, Francesco Paolo Tambaro, MD, PhD1*, Nashat Gabrail3*, Ahmed Nadeem, MD4*, Tapan Kadia, MD5, Elias Jabbour, MD1, Gautam Borthakur, MD1, Stefan Faderl, MD1, Willie Newsome, RN1*, Hui Yang, MD, PhD1*, Kevin Chen6*, Karen Stein, MD6* and Hagop Kantarjian, MD1 Monday, December 7, 2009: 3:15 PM R06-R09 (Ernest N. Morial Convention Center) Oral Session NA 591 Genome-Wide Analysis of DNA Methylation Patterns Reveals Dynamic Epigenetic Regulation of the AML Genome After Decitabine Treatment DNA甲基化模式的全基因组分析揭示地西他滨治疗后AML基因组的动态表观遗传学调节作用。 Fabienne Brenet, Ph.D.1*, Michelle Moh, MS1*, Patricia Funk, BS1*, Daoqui You, MS2*, Agnes J. Viale, Ph.D.2*, Nicholas D. Socci, PhD3* and Joseph M. Scandura, MD, PhD4 Saturday, December 5, 2009, 5:30 PM-7:30 PM Hall E (Ernest N. Morial Convention Center) Poster Poster Board I-791 1769 Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine 低危及中危MDS患者使用地西他滨治疗MDS同时使用血小板生成药物Romiplostim的疗效和安全性研究 Saturday, December 5, 2009, 5:30 PM-7:30 PM Hall E (Ernest N. Morial Convention Center) Poster Poster Board I-75 [1053 Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome- Outcome in Previously Untreated Patients 地西他滨联合吉姆单抗奥佐米星治疗初治的AML和高危MDS的2期研究 Gautam Borthakur, Guillermo Garc